Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 22

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 22
---
 from the sale of the divested business, if and when it is sold, through mechanisms including Contingent Value Rights. It should be noted that if the divested business generates negative cash flow and/or profitability at the end of any fiscal quarter (except for intellectual property maintenance costs of up to $100,000 per calendar year), the combined company will have the right to cease the sale process of the divested business and take any action regarding it as deemed appropriate. Proposal:The Board of Directors proposes that the CVR Agreement be approved on an advisory basis. 13.Approval of Option and RSU Conversion on an advisory basis Explanation:The Company intends to convert outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at the time of the completion of the transactions contemplated by the Merger Agreement (the “Conversions”). The NLS Common Shares underlying options and RSUs shall be transferred to a trustee and subsequently to the holder upon exercise of the option or once the entitlement to the share underlying the RSU arises. Proposal:The Board of Directors proposes that the Conversions be approved on an advisory basis. ******* [voting instructions and appendices follow] Voting Instructions: Please note the following instructions with respect to the participation in the extraordinary shareholders’ meeting: 1.Voting rights Shareholders who are entered in the shareholder register maintained by our transfer Agent, VStock Transfer, LLC as of, 2025 11:59 pm CET (recording date), are entitled to participate personally or be represented as provided for herein in order to exercise their shareholder rights with respect to this extraordinary shareholders’ meeting. During the period from, 2025 until and including, 2025, no entries of shares will be made in the shareholder register. Shareholders who sell part or all of their shares before this extraordinary shareholders’ meeting are no longer entitled to vote to that extent. They are asked to return or to exchange their voting material. 2.Personal Participation or Representation Shareholders are kindly requested to return to NLS Pharmaceutics Ltd., Alexander Zwyer (CEO) per postal mail (The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -pharma.com) the attached registration form (Appendix 1) duly completed and signed latest until(received by 11:59 pm CET). 3.Representation In the event that you do not intend to participate personally in this extraordinary shareholders’ meeting, you may be represented by the independent proxy, K